Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
株式のランク #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
株価
$0.11725176
最終同期: 2025-07-14
時価総額
$481.50K
変化(1日)
-0.20%
変化(1年)
0.00%
FR
取引 PHAXIAM Therapeutics S.A. (PHXM)

カテゴリー

PHAXIAM Therapeutics S.A.(PHXM)のEPS
June 2024 時点のEPS TTM: $-4.23
PHAXIAM Therapeutics S.A.の最新の財務報告と株価によると、同社の現在のEPS(TTM)は$-4.23です。2022年末には、EPSは$-0.07で、2021年のEPS$-23.87と減少でした。
PHAXIAM Therapeutics S.A.のEPS履歴(2016から2026まで)
各年末時点のEPS
EPS 変化
2026 (TTM) $-4.23 -23.50%
2023 $-5.53 7,492.45%
2022 $-0.07 -99.69%
2021 $-23.87 -46.82%
2020 $-44.88 23.87%
2019 $-36.23 60.03%
2018 $-22.64 -30.76%
2017 $-32.70 21.96%
2016 $-26.81 0.00%
同様の企業または競合他社のEPS
企業 EPS EPSの差
$17.32 -509.44%
US
$27.74 -755.76%
NL
- -
CH
- -
KR
$13.70 -423.86%
BE